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THIS communication is part of a study of the immunosuppressive activity of the anti-tumour agent busulphan. There are two peculiarities in the behaviour of the drug which render this activity worth investigating. First, its haematological and histological effects are predominantly upon the erythroid, platelet and myeloid systems, its observable effects on lymphoid organs and circulating lymphocytes being trivial except at supralethal doses (Elson, Galton, and Till, 1958; Sternberg, Phillips and Scholler, 1958) . Thus, the very system most intimately connected with an immune response is apparently spared. Second, busulphan, though an alkylating agent, is very much more active when administered before antigen than afterwards. This contrasts with most other immunosuppressive alkylating agents, which generally act best when administered after the antigen (Berenbaum, 1967) .
Cysteine is one of a group of chemicals which protect against the toxic effects of radiation and so-called " radiomimetic " agents (Connors, 1966) . It has been shown that the immunosuppressive activity as well as the toxicity of one such agent, nitrogen mustard, is reduced by the administration of' cysteine (Berenbaum, 1966) . It seemed appropriate to extend this study to busulphan as it is known to react with thiol groups in vivo (Roberts and Warwick, 1959) and because this latter reaction may be of importance in its mechanism of action (see discussion).
For comparative purposes, nitrogen mustard and cyclophosphamide were also studied, because the toxicity of both is known to be reduced by eysteine (Brandt and Griffin, 1951; Connors, 1966; Brinckner, 1964) .
MATERIALS AND METHODS
Animals.-BALB/c female mice were used, weighing 14-20 g. at the start of the experiment.
DrUg&-(All materials were diluted so that the required amount was contained in 0-I ml./10 g. body wt.) (1) Cyclophosphamide (pure substance, batch 6066, Ward, Blenkinsop and Co. Ltd., London) was dissolved in saline immediately before use; the solution was given subcutaneously.
(2) Busulphan (Burroughs Wellcome and Co., Batch AN 31911) was administered as a suspension in dehydrated arachis oil (see Berenbaum, Timmis and Brown, 1967, for (Fig. 1) . Cysteine strongly inhibited the immunosuppressive activity of the drug. Cyclopho8phamide after antigen (day + 2): Fig. 2 illustrates one of two experiments in which eysteine significantly and markedly counteracted the immunosuppressive activity of cyclophosphamide at all doses (P < 0-05). Two single dose experime'nts were performed using a large dose of drug (300 mg./kg., Fig. 3 ). The effect on immunosuppression was much less than that seen with smaller doses (the reduction was 2-5-fold compared to 10-to 100-fold), and in only one of the two experiments (M304) was this reduction significant (P 0-01-0-02). Bmulphan before, antigen (-7 hr and day 1) In an initial experiment a single dose of 90 mg./kg. was given 7 hours before the antigen (Fig. 4) (Fig. 6) . Again, an enhancement of immunosuppressive activity was seen (P 0-01-0-002 for 90 mg./kg. dose) but only with the fresh suspension. To summarize, eysteine never inhibited the immunosuppressive effect of busulphan given before the antigen; at times it significantly increased i't. 
Bmulphan after antigen (day +2)
Two experiments were performed (Fig. 7) . In the first experiment no significant suppression was obtained with 90 mg./kg.; in contrast, the suppression obtained with busulphan plus eysteine was significant (P 0-05-0-025).
In the second experiment, significant suppression was obtained with this dose of busulphan and, to a greater degree, with busulphan plus cysteine. 
DISCUSSION
The toxicity of several alkvlating agents is reduced by eysteine, and Connors (1966) summarized evidence that protection is due to a direct reaction between the drug and cysteine, rather than any indirect mechanism. The immunosuppressive effects of nitrogen mustard and cyclophosphamide are also reduced by administration of eysteine. In the case of nitrogen mustard, this is probably due to a direct reaction with cysteine before the alkylating agent is able to damage crucial sites in cells mediating antibody production. In the case of cyclophosphamide, a direct reaction is unlikely as this drug is largely un-ionized in vitro while, in vivo, cyclophosphamide is oxidized in the liver to as yet unidentified metabolites (Brock 1967; Brock and Hohorst, 1967; Friedman, 1967) (Brincker, 1964) and the level of protein-free thiol in the spleen returns to normal 21 hours after an injection of I g./kg. (Connors, 1966) . This difference in in vivo half-lives may account for the failure of a number of attempts to reduce the effects of busulphan with thiol compounds (Asano, Odell, McDonald and Upton, 1963; Ochoa and Hirschberg, 1967 (Ross, 1962) . These local concentrations are unknown and the reactivities of these groups at the relevant in vivo sites will depend in part on the local molecular environment. It is possible, therefore, that even when eysteine is present at the crucial reaction site, busulphan may still react preferentially with its normal target molecule(s). (Roberts and Warwick, 1961) . It has been suggested that interference with the many enzyme systems containing thiol groups might underlie the toxic effects of busulphan (Calabresi and Welch, 1965) .
Part of the attraction of the thiol-combining hypothesis lies in the failure to detect cross-linking of DNA with busulphan at biologically important doses. This is believed to be the lesion initiating the biological effects of most other alkylating agents (Ross, 1962; Alexander, 1969 (Verly and Brakier, 1969) . Some other explanation must therefore be sought for its effects. Doubt has been thrown on dethiolation as the mechanism by which busulphan exerts its effects because the in vivo pool of thiol-containing compounds would seem to be too large to be affected significantly by doses of busulphan in the clinical range (Boesen and Davis, 1969) . Nevertheless, Harrap and Speed (1964) showed that administration of busulphan in chronic myeloid leukaemia led to a fall in leucocyte glutathione, and the doses required for immunosuppression in the mouse (60 mg./kg. or m6re) may be more effective in depleting particular tissue thiols than the much smaller doses (0-065 mg./kg./day) used in man. However, the findings of Harrap and Speed (1964) might well have been secondary to other changes in the leukaemic cell population.
The experiments reported here also throw doubt on the thiol-depletion hypothesis, for administration of excess exogenous thiol with busulphan, far from ameliorating the immunos'uppressive effects of the drug, actually potentiated them. It would be premature to speculate on the reasons for this effect, but it raises the possibility that it is not busulphan itself that causes cell damage, but a metabolite produced by the reaction between busulphan and thiols. One such product (the major urinary metabolite, 3-hydroxy-tetrahydrothiophene-1, 1-dioxide) was found to be relatively non-toxic in the rat and rabbit by Roberts and Warwick (1961) , but these authors pointed out that cells might be impermeable to this substance and that its production inside cells might be damaging (Roberts and Warwick, 1959) .
